Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
Subscribe To Our Newsletter & Stay Updated
